<DOC>
	<DOCNO>NCT02113397</DOCNO>
	<brief_summary>The purpose study characterize bacterial diversity richness sputum cystic fibrosis patient treat every-other-month TOBI™ Podhaler™ continuous alternate therapy TOBI™ Podhaler colistimethate ( Colistin ) .</brief_summary>
	<brief_title>Evaluation Inhaled Antibiotics Bacterial Diversity Richness Cystic Fibrosis Lung</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Diagnosis cystic fibrosis confirm mutation analysis cystic fibrosis transmembrane conductance regulator gene Sputum throat swab culture positive Pseudomonas aeruginosa within 6 month enrollment Age ≥12 year Forced expiratory volume one second ( FEV1 ) 2590 percentpredicted Age &lt; 18 year Inability routinely expectorate sputum without induction hypertonic saline Inability provide withdrawal write informed consent History aminoglycoside sensitivity adverse reaction inhale antibiotic Serum creatinine ≥ 2.0 mg/dl Serum blood urea nitrogen ( BUN ) ≥40 mg/dl Pregnancy lactate screen History systemic intravenous antiPseudomonal antibiotic within 28 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Microbiome</keyword>
	<keyword>Sputum</keyword>
	<keyword>Tobramycin</keyword>
	<keyword>Colistimethate</keyword>
</DOC>